Safety of an IV formulation of carbamazepine

Jeannine M. Conway; James R. White; Angela K. Birnbaum; R. Eugene Ramsay; Page B. Pennell; John O. Rarick; Luna Musib; Ilo E. Leppik; James C. Cloyd

doi:10.1016/j.eplepsyres.2009.01.013

Safety of an IV formulation of carbamazepine

Jeannine M. Conway, James R. White, Angela K. Birnbaum, R. Eugene Ramsay, Page B. Pennell, John O. Rarick, Luna Musib, Ilo E. Leppik, James C. Cloyd

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100 mg of study drug as replacement for 100 mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.

Original language	English (US)
Pages (from-to)	242-244
Number of pages	3
Journal	Epilepsy Research
Volume	84
Issue number	2-3
DOIs	https://doi.org/10.1016/j.eplepsyres.2009.01.013
State	Published - Apr 2009

Bibliographical note

Funding Information:
This work was supported by NIH-NINDS P50-NS16308, NCRR M01-RR00400, M01-RR00039, and M01 RR16587.

Keywords

Adults
Carbamazepine
Elderly
Epilepsy
Intravenous

Access

10.1016/j.eplepsyres.2009.01.013

OpenUrl availability

Full text

Cite this

@article{8e8baedca68a44668f4b34d99a8cf045,

title = "Safety of an IV formulation of carbamazepine",

abstract = "An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100 mg of study drug as replacement for 100 mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.",

keywords = "Adults, Carbamazepine, Elderly, Epilepsy, Intravenous",

author = "Conway, {Jeannine M.} and White, {James R.} and Birnbaum, {Angela K.} and {Eugene Ramsay}, R. and Pennell, {Page B.} and Rarick, {John O.} and Luna Musib and Leppik, {Ilo E.} and Cloyd, {James C.}",

note = "Funding Information: This work was supported by NIH-NINDS P50-NS16308, NCRR M01-RR00400, M01-RR00039, and M01 RR16587.",

year = "2009",

month = apr,

doi = "10.1016/j.eplepsyres.2009.01.013",

language = "English (US)",

volume = "84",

pages = "242--244",

journal = "Epilepsy Research",

issn = "0920-1211",

publisher = "Elsevier",

number = "2-3",

}

TY - JOUR

T1 - Safety of an IV formulation of carbamazepine

AU - Conway, Jeannine M.

AU - White, James R.

AU - Birnbaum, Angela K.

AU - Eugene Ramsay, R.

AU - Pennell, Page B.

AU - Rarick, John O.

AU - Musib, Luna

AU - Leppik, Ilo E.

AU - Cloyd, James C.

N1 - Funding Information: This work was supported by NIH-NINDS P50-NS16308, NCRR M01-RR00400, M01-RR00039, and M01 RR16587.

PY - 2009/4

Y1 - 2009/4

N2 - An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100 mg of study drug as replacement for 100 mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.

AB - An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100 mg of study drug as replacement for 100 mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.

KW - Adults

KW - Carbamazepine

KW - Elderly

KW - Epilepsy

KW - Intravenous

UR - http://www.scopus.com/inward/record.url?scp=64149115100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149115100&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2009.01.013

DO - 10.1016/j.eplepsyres.2009.01.013

M3 - Article

C2 - 19299110

AN - SCOPUS:64149115100

SN - 0920-1211

VL - 84

SP - 242

EP - 244

JO - Epilepsy Research

JF - Epilepsy Research

IS - 2-3

ER -

Safety of an IV formulation of carbamazepine

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this